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The intrathecal route of morphine: why its clinical
application in postoperative pain is still so limited
Historical perspective
The isolation of morphine from opium by Seturner in 1803 and the
introduction of the syringe and hollow needle to clinical practice by Wood
in 1853 finally permitted opioids to be administered in carefully measured
doses (Foldes 1964). Morphine was frequently used intramuscularly for
preoperative medication as a supplement during ether and chloroform
analgesia. In the late nineteenth century large amounts of morphine (1 to 2
mg/kg) were administered in divided doses intravenously, intramuscularly
or both, as a complete anesthetic. Although initially popular, this technique
was abandoned because of an alarming increase in operative morbidity and
mortality. For the next 30 to 40 years, anesthesiologists rarely used narcotic
analgesics intraoperatively. Introduction of ultra short-acting barbiturates as
intravenous anesthetics and acceptance by anesthesiologists of the concept
of balanced anesthesia renewed enthusiasm for the intraoperative use of
opioids. In addition, opioids were used for postoperative analgesia by
intramuscular or subcutaneous route (Miller 1986).
Systemically administered opioids: adverse effects
Presently, the most common method to bring about postoperative analgesia
remains intramuscular or subcutaneous administration of opioids. However,
these systemically, administered opioids cause a variety of adverse effects
(table 1). Although a single effect - pain relief - is pursued, the incidence of
adverse effects is high. Thus far, the ideal analgesic, powerful and devoid of
adverse effects, remains to be found.
    Table 1. The most common adverse effects of systemically administered opioids
Hypotension Bradycardia Respiratory depression
Nausea and vomiting Constipation Sedation
Drowsiness Miosis Physical dependence
Urinary retention Dysphoria
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Opioid receptors
Over the last decades there has been a growing understanding of the
mechanisms of action of opioids. The opioids receptors are found in the
brain and spinal cord where they generate their analgesic effects. In 1973
three independent investigators described the presence of an opioid
receptor in nervous tissue and hypothesized that endogenous substances
probably stimulate this structure (Hughes 1973, Kosterlitz 1973, Terenius
1973). At this moment multiple types of opioid receptors are recognized.
Specifically, the m, k, and d types and their subtypes are recognized to
mediate the analgesic effects of opioid drugs.
Alternative routes of administration of opioids, a peer review
The brain, the spinal cord and the spinal roots were considered as three
potential major targets for pain control. When opioids are administered, the
brain and spinal cord are the main site of action. For local anesthetics, the
spinal cord and spinal roots are the target sites (table 2).
Table 2. The target site for analgesic action of opioids and local anesthetics.
Brain Spinal cord Spinal roots
Intravenous opioids +++ + -
Intramuscular opioids +++ + -
Epidural opioids ++ ++ -
Intrathecal opioids + +++ -
Intrathecal local
anesthetics
- ++ +++
Epidural local
anesthetics + opioids
++ ++ +++
Intrathecal local
anesthetics + opioids
+ +++ +++
For the opioids, the recognition of the importance of the sites of action
resulted in the innovation of techniques and methods of administration: i.e.
their regional application. Although opioid drugs can be administered in a
selective fashion to the supraspinal structures selected, this approach is both
difficult and hazardous. Moreover, the most frequent and dangerous
adverse effects (see table 1) are caused by the supraspinal action of opioids.
In contrast, the spinal cord is easily accessible by the conventional epidural
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or intrathecal route. Likewise for local anesthetics these routes are
customary and after such selective administration these drugs act at the
nerves, nerve roots or spinal cord. Taken together, the epidural and
intrathecal routes are logical for combined administration of opioids and
local anesthetics.
The effects of perispinal opioids
In 1979, two reports acted as catalysts to promote further studies with
spinal administered opioids. Wang et al. reported on the efficacy of
intrathecal morphine to relieve unbearable malignant pain in 8 patients
(Wang 1979). Behar et al. reported on the efficacy of morphine by epidural
route in chronic pain patients (Behar 1979). Both authors pointed out that
intrathecally-injected opioids are actually administered in close proximity to
the opiate receptor site: i.e. at the place of effectiveness. After the first
human administration of intrathecal morphine (Wang 1979), the
effectiveness of opioids administered by the intrathecal route was studied
for various painful conditions: i.e. malignant pain, chronic pain and
postoperative pain. For treatment of malignant and chronic pain syndromes
the use of intrathecal morphine gained rapid and general acceptance,
particularly for patients who had used opioids by the oral route.
The aim of the intrathecal and epidural administration of opioids was to
apply the drug as close as possible to the effector site in order to achieve
maximal therapeutic effect with minimal adverse effects. The term
“selective spinal analgesia” suggested by Cousins et al. (Cousins 1979)
emphasizes the difference between analgesia obtained with relatively non-
selective blockade of axonal conduction of local anesthetics and the highly
selective actions of spinal opioids. Indeed, for intrathecal morphine the
analgesic doses of morphine are only 1 – 2% of the systemic dose of
morphine. Animal studies showed that intrathecal opioids are even effective
after a dose of approximately 1/100 th. of the intravenous dose (Dirksen
1985). Thus, based on these data one may expect orthopedic surgical
patients to be less drowsy, to recover faster and to be more co-operative
after surgery. Moreover, the unique feature of intrathecally or epidurally
administered opioids is the highly analgesic selective action with a nearly
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complete lack of sensory (involving C and Ad fibers), sympathetic, or motor
block. This allows orthopedic surgical patients to ambulate without the risk
of orthostatic hypotension or motor in-coordination that local anesthetics
cause (intrathecal or epidural).
Unfortunately, the final result of selective administration by the perispinal
route was not as ideal as expected. Specifically, a high incidence of nausea
and vomiting, urinary retention, and itching was reported after intrathecal
administration of opioids for postoperative pain relief (Carpenter 1992).
Less common but extremely dangerous is the late respiratory depression
that may occur 6 to 12 hours after intrathecal administration of opioids. It
was recognized that the adverse effects following intrathecally-administered
morphine (table 3) could be primarily explained by the action of opioids at
supraspinal areas (Payne 1985). High doses of intrathecally-administered
morphine are likely to progressively produce effects on systems other than
the primary site of action. Thus regardless of the route, the administration
of opioids may result in a dose-related manner adverse effects, including
dangerous apnea.
 Table 3. Adverse effects encountered after a
 single dose of intrathecal morphine for
 postoperative pain relief.
Postoperative nausea and vomiting
Urinary retention
Pruritus
Sedation
Respiratory depression
Constipation
Noteworthy, - and in addition to above mentioned adverse effects - there is
no conclusive evidence that intrathecally injected opioids yield a higher
quality of postoperative pain relief when compared to that produced by
systemic opioids.
Taken together, the benefit of excellent postoperative pain relief after
intrathecally administered morphine was observed in several clinical studies,
Chapter 1
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but the above mentioned adverse effects prove that the goal of a “selective
spinal analgesia” has still not been achieved (optimal analgesic effect /
minimal adverse effects).
In considering how to approach the goal “selective spinal analgesia” the
physicochemical characteristics and dose of the selected opioids have to be
considered.
Physicochemical characteristics
The distribution of intrathecally administered opioids between the water
(cerebrospinal fluid) and fat (nervous structures, membranes) phase is
determined by the hydro - / lipophilicity and the magnitude of the ionized
fraction. Highly water-soluble drugs with large ionized fraction will linger in
the water phase (CSF) and ascend rostrally. Therefore, the lipid solubility is
an important property that contributes to the likelihood of respiratory
depression. Moreover, lipophilic drugs with large unionized fraction will
cross the lipid barriers fast and easily. Thereby, they will get access to the
receptor sites and they will be eliminated fast, with little tendency to linger
in the water phase.
Fentanyl and sufentanil are examples of the highly lipid-soluble opioids. It is
in agreement with this property that these drugs show a rapid onset of
action with minimal residual cerebrospinal fluid concentrations, which may
ascend rostrally to the brain. In contrast, morphine is a typical water-soluble
drug. Its slow onset of action after intrathecal injection coincides with a late
peak concentration in cerebrospinal fluid. Its relative hydrophilicity results
in slower efflux from the spinal cord and cerebrospinal fluid resulting in
greater migration to the brain.
Although in apparent contradiction with the above, it is precisely the high
degree of hydrophilicity that makes morphine the drug of choice for
intrathecal administration. Its hydrophilicity underlies the long-term
presence of the drug in the cerebrospinal fluid and thereby its long lasting
analgesic effects up to 24 hours (Chauvin 1982) or more.
The intrathecal route
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Optimal dose
Since the first human administration of intrathecal morphine in man in 1979
we are still looking for the optimal dose: the dose that will cause the best
analgesia and the least adverse effects. This technique has been applied
widely in anesthesia but the optimal dose of morphine to cause excellent
analgesia with minimal adverse effects has still not been established.
Noteworthy, it was soon recognized that the doses initially administered
were indeed far too high, and gradually lower dosages were introduced.
Fig 1a. History of intrathecal morphine dose 
in total hip surgery (highest dose).
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Fig 1b. History of intrathecal morphine dose 
in total hip surgery (lowest dose)
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Dosages for intrathecal morphine found in literature range from 0.1 to 4 mg
for total hip surgery (see figure 1a and 1b).
The goal is to achieve maximum analgesic effect with as little adverse effect
as possible. This goal can be achieved by using the intrathecal route of
Chapter 1
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administration but not the oral, subcutaneous or intravenous route. Further
improvement of the analgesic effect and minimizing the incidence of
adverse effects can be pursued by: 1. studies that define the optimal dose of
morphine in different types of surgery and 2. developing endorphino
mimetic drugs, specifically tailored for perispinal use.
19
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Aim of the study
Surgery and anesthesia are associated with postoperative sequelae such as
pain, nausea and vomiting, drowsiness, sleep disturbances, respiratory and
circulatory complications, hypothermia, urinary retention and other
unfavorable experiences. The incidence of these sequelae is different in
various surgical procedures. Orthopedic surgery is characterized by a high
incidence of severe postoperative pain, urinary retention, and nausea and
vomiting in the postoperative period (Carpenter 1992). Severe postoperative
pain is known to adversely affect patient outcome after a variety of surgical
procedures. (Jamison 1993, Ready 1996). Under treatment of pain may
impede short-term recovery and may even have a detrimental long-term
effect on health (Liebeskind 1991, Jänig 1994). Excessive analgesic drug
administration may cause a high incidence of the above-mentioned adverse
effects in the postoperative period. Therefore, appropriate pain
management for postoperative patients may contribute to improved
recovery and in orthopedic surgical cases to earlier mobilization, optimal
early rehabilitation, a short postoperative hospital stay and a reduction in
costs (ASA report 1995).
The Sint Maartenskliniek, Nijmegen is a 333 bed categorical hospital in the
eastern part of the Netherlands and has traditionally specialized in
Orthopedic Surgery. The operating room department has four operating
rooms available. In 1996, when one anesthetist and a number of nurse
anesthetists were available for clinical work in the operating rooms only,
3300 orthopedic surgical procedures were performed annually. From 1996
to 1999 there was an increase in orthopedic operations of 20 %. Nowadays,
four anesthesiologists are working in the hospital, not only for clinical work
in the operating rooms, but also involved in: the preoperative evaluation of
patients in an out patient clinic; postoperative critical care and pain
management; pain service for patients suffering from chronic pain; and,
scientific research. This increase in activities has contributed to an improved
quality of clinical care.
Aim of the study
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The postoperative pain management in the Sint Maartenskliniek has
changed considerably in the last few years. In this thesis several clinical
aspects of the change in postoperative pain management of major
orthopedic surgery of the lower limb is described. In 1996 it was considered
necessary to improve the postoperative management of pain, in order to
reduce suffering of patients and to avoid of suboptimal conditions for
rehabilitation of patients following orthopedic surgery. In view of the
considerations given in the first chapter of this thesis, we considered
whether to use the intrathecal or the epidural route of administration of
opioids and local anesthetics. Several aspects were taken into consideration
before a final conclusion was made. Two alternatives were specifically
considered: the use of a continuous epidural catheter or the intrathecal
administration of analgesics using a single shot technique (table 1).
Table 1. Differences of epidural catheter and intrathecal single shot technique
Properties of drugs Epidural catheter Intrathecal single
shot
Onset of local anesthetics Slow Fast
Onset of morphine Slow Slow
Dosage of morphine High Low
Dosage of local anesthetics High Low
Technique
Catheter Necessary Not necessary
Infusion pumps Necessary Not necessary
Technique failures Possible Rare
Chapter 2
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Table 1. continued.
Financial costs
Epidural catheter Intrathecal single
shot
Drugs High Low
Materials High Low
Manpower High Low
Education level High Low
Technique related side effects Epidural catheter Intrathecal single
shot
Post spinal puncture headache No Yes
Late respiratory depression Dependent on dose Possible at low
doses
Motor dysfunction after 24 hours Yes No
Problems 12 hours after induction Technique failures Respiratory
depression
Perforation of dura 0.5% by catheter 100%
Unnoticed high block Possible No
Finally we have chosen the intrathecal single shot technique with
bupivacaine and morphine. The main considerations that made us to select
this technique were:
1. Fast onset to surgical anesthesia;
2. Adequate postoperative pain relief in the first hours following surgery;
3. Minimal need for extra additional manpower to assist in technical
problems with continuous catheter techniques in the first 24 hours
postoperatively;
4. Limited need for training of ward nurses with a new technique
(epidural);
5. Cost/effectiveness.
Following our hypothesis that the intrathecal route – from the theoretical
point of view – would be the optimal one for administration of morphine to
achieve adequate post postoperative pain relief after major orthopedic
surgery of the lower limb with a low incidence of adverse effects. Indeed
analgesia was judged to be improved when compared to the pain relief
regime in the past, using intramuscular opioids. Our ward nurses noticed an
Aim of the study
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unexpectedly high incidence of adverse effects. Especially nausea and
vomiting, urinary retention, and itching were observed to be important
drawbacks of the intrathecal opioid technique.
In considering this outcome we hypothesized that a reduced dose intrathecal
morphine still produce similar pain relief scores but with minimization of
the incidence of adverse effects.
To answer this question, a randomized, double-blind trial was undertaken to
establish the optimum dose of intrathecal morphine in terms of adequate
pain relief after total hip surgery and to evaluate whether the lowest
effective dose indeed was associated with a reduction of adverse effects
(Chapter 3). Two relevant practical aspects were specifically highlighted.
First, a major problem in the practical study design was that the
pharmaceutical companies do not provide mixtures of local anesthetics and
opioids for intrathecal application in man. We recognized that precisely
defined dosing was necessary for this study. Therefore, we to designed and
described the method of preparation of a morphine/bupivacaine mixture
for intrathecal administration (Addendum).
Second, studies in experimental animals had suggested that pre-emptive
analgesia might improve the quality of postoperative pain management
(Brennan 1997). That’s why we examined whether the severity of
preoperative pain was related to postoperative pain levels and morphine
intake in patients undergoing first hip replacement (Chapter 4).
Next to the evaluation of analgesic effectiveness, the aim of our studies was
to study in detail the incidence of adverse effects and to evaluate which
factors might contribute. Therefore, specific attention was paid to the most
prominent adverse effects following orthopedic surgery and anesthesia: post
operative nausea and vomiting (PONV), itching, and urinary retention.
One of the most distressing side effects related to the use of intrathecal
morphine is postoperative nausea and vomiting (PONV). However, several
factors affect the incidence and severity of this complication. Actually it is
not known to which extent low doses of intrathecal opiates cause or
Chapter 2
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contribute to PONV? Therefore, we investigated the relationship of PONV
and intrathecal opiate by comparing the incidence of PONV in patients who
received intrathecal bupivacaine for surgery and postoperative pain relief to
the incidence of PONV in patients who were given bupivacaine plus
morphine. Since metoclopramide was found to be the best drug to reduce
PONV after intrathecal anesthesia in orthopedic patients (Spelina 1984) we
investigate the potential usefulness of this anti-emetic in the treatment of
PONV in orthopedic patients who received intrathecal morphine (Chapter
5).
Another very disturbing adverse effect induced by intrathecal morphine is
itching. This adverse effect was evaluated in Chapter 6.
In this study we addressed the following questions:
1) Is itching a dose dependent phenomenon following intrathecal morphine
administration and is itching reduced following the lower doses of (0.025 –
0.2 mg) intrathecal morphine?
2) Does systemically administered morphine contribute to the problem of
itching; and,
3) How well can itching, caused by low doses of intrathecal morphine, be
managed by applying a standardized treatment using promethazine and -
for intractable itch – naloxon (Chapter 6).
Another frequently observed adverse effect associated with surgery and
anesthesia is urinary retention. Kamphuis et al. observed that the function
of the lower urinary tract following intrathecal anesthesia remains disturbed
long after the intrathecal regional blockade has worn off (Kamphuis 1998).
This contributes to postoperative urinary retention and to postoperative
discomfort. Evaluation of the filling of the urinary bladder in postoperative
period by physical examination has always been an inaccurate method.
Recent development allow for assessment of the volume of the bladder
non-invasively and with reasonable accuracy by ultrasound (Coombes 1994).
We considered that this measurement could be applied for a more logical
approach to the decision whether to pass a urinary catheter in patients after
Aim of the study
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intrathecal anesthesia or not. This topic was investigated in a study using the
BladderScan® in Chapter 7.
Chapter 2
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Chapter 3
Optimization of the dose of intrathecal morphine in total
hip surgery: a dose finding study
This study has been published:
Optimization of the dose of intrathecal morphine in total hip surgery: a dose
finding study. R. Slappendel, E.W.G. Weber, R. Dirksen, M.J.M. Gielen, J.
van Limbeek. Anesth. Analg. 1999; 88 (4): 822-6.
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Optimization of the dose of intrathecal morphine in total
hip surgery: a dose finding study
Introduction
Many studies (Domsky 1992, Kalso 1983, Grace 1996, Reat 1989) have
shown that intrathecal administration of morphine provides excellent
postoperative pain relief in major orthopedic surgery. However use of spinal
morphine was often associated with unpleasant side effects such as urinary
retention, pruritus and postoperative nausea and vomiting (PONV)
(Cousins 1984). Moreover, early studies reported late respiratory depression
in some cases, but intrathecal doses of morphine as high as 2.5 mg were
used (Reay 1989, Jacobson 1988, Gustafsson 1982).
The water-soluble nature of morphine contributes to the longevity of its
analgesic effect, and allows the rostral ascent (Max 1985, Payne 1985) that
underlies the risk of late respiratory depression. The cerebrospinal fluid
opioid concentration is dose dependent (Nordberg 1984), as are both
analgesia and respiratory depression (Bailey 1993). Profound and prolonged
respiratory depression was reported by Bailey et al. (Bailey 1993). after an
intrathecal dose of 0.6 mg, and minimal, yet statistically significant,
respiratory depression occurred even after 0.15 mg morphine (Yamaguchi
1990).
We hypothesized that even lower doses might further minimize side effects,
but were unclear whether these doses would offer the desired analgesic
effect. For these reasons, a randomized, double-blind trial was undertaken
to establish the optimum dose of intrathecal morphine that effectively
relieves pain after total hip surgery and to evaluate whether the lowest
effective dose indeed coincides with minimized side effects.
Methods
The study was approved by the ethical committee of our hospital and
written informed consent was obtained from all patients. One hundred
forty-three consecutive patients (ASA 1-3) scheduled for total hip surgery
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during intrathecal anesthesia were included in the study in a prospective,
randomized, double-blind manner.
All patients were premedicated with 5, 7.5, or 10 mg midazolam (0.1 mg/kg)
orally one h before spinal anesthesia. Intrathecal anesthesia (27 gauge
quincke needle) was produced by administering 20 mg bupivacaine plus
morphine dissolved in 4 mL. Patients were allocated to four groups: Group
I,  0.025 mg, Group II, 0.05 mg, Group III, 0.1 mg and Group IV, 0.2 mg
morphine. The delivered morphine dose was known to the pharmacist in
case of an adverse event.
The anesthesiologist administered 1 mg midazolam at the minimum interval
of 5 min until the patient indicated that the desired sedation was achieved.
Non-invasive blood pressure, heart rate (electrocardiogram), oxygen
saturation (SpO2), and respiratory frequency were continuously monitored
during anesthesia and in the intensive care unit during the first 24 h after
surgery.
In the post-operative period, all patients were treated with the nonsteroidal
anti-inflammatory drug nabumeton 1500 or 2000 mg orally (first dose: one
h before surgery), 1 dose a day (30 mg/kg). If nabumeton was
contraindicated, oral paracetamol was given (70 mg/kg, 6 times a day). Pain
was evaluated using visual analog scores (VAS. VAS ranges from 0 - 10;
with 0 = no pain and 10 = most severe pain).  For each individual patient
we assessed the highest VAS score in  the 24 h period and total pain VAS
scores [area under the curve (AUC) of VAS scores in the 24 h period]. If
pain was present morphine was administered intravenously by patient
controlled analgesia (PCA) pump. The settings of the PCA pump
(BRAUN®, Melsungen, Germany) were: baseline 0.0 mg/h, bolus dose 1.0
mg, bolus interval 5 min, maximum 30 mg dose per 4h.
PONV were treated according to the standard protocol. The first step was
10 mg metoclopramide intramuscularly, followed by 10 mg metoclopramide
intramuscularly after one h when necessary. If symptoms persisted 1.25 mg
droperidol was given, and finally 5 mg tropisetron both intravenously. Each
step was initiated by patient request. The minimum interval between each
step was one h.  PONV was evaluated from the following data: 1) the
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patient’s subjective feeling (the presence or absence of subjective nausea); 2)
the patient’s request to be treated with an antiemetic; and, 3) the actual
consumption of antiemetics.
Other side effects scored in the postoperative period included: respiratory
depression (defined as breathing frequency below 10 per min and arterial
blood gas showing acidosis and hypercarbia); itching (by specific inquiry and
recording of the antipruritic medication (promethazine)); urinary retention
(defined as absence of spontaneous voiding at 7 h after surgery and volume
at catheterization of > 400 mL); hypotension (> 25% reduction of
preoperative mean arterial blood pressure); and bradycardia (heart rate
below 40 bpm). The presence or absence of any of these side effects was
noted at 3 h intervals during the 24 h observation period. Also, the
medication for treatment of any of these side effects was registered at the
same intervals during the 24 h observation period.
Analysis of interval scored data as performed using analysis of variance
techniques or t-tests (paired or unpaired respectively depending on data
structure). Non-parametric techniques (Kruskall Wallis) were used when
necessary. Post-hoc analysis was done by using the Duncan test with
significance level of p = 0.05. Proportions were analyzed with Chi-square
statistics and Fischer’s Exact test. The alpha level for all analysis was set on
p=0.05. Data are reported as means (SD).
Results
Demographic data and intraoperative factors are given in  Table I. The four
groups did not differ in age, height, weight or gender. Also, the patient
groups were not different in any other characteristics; e.g.: the preoperative
use of beta blockers; the magnitude of blood loss during surgery; the
percentage of patients who got sedation during surgery; use of cementation
and concurrent blood pressure drop.
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Table I.  Demographic data and intraoperative factors.
Group
I II III IV
Intrathecal morphine (mg) 0.025 0.05 0.1 0.2
N 35 37 37 34
Age (years) 63 (13) 66 (9) 62 (15) 63 (11)
Height (cm) 168 (8) 170 (8) 170 (7) 168 (9)
Weight (kg) 70 (11) 74 (14) 75 (11) 74 (14)
Gender (m.f) 12, 23 10 , 27 10 , 27 7 , 27
Sedation during surgery (%) 77.1% 86.5% 83.8% 85.3%
Beta blocker use preoperatively
(%)
20.0% 18.9% 13.5% 14.7%
Intra operative blood loss (mL) 614 (290) 559 (305) 595 (261) 526 (260)
Cementation 77.1% 64.9% 56.8% 50.0%
Blood pressure drop following
cementation
5.7% 8.1% 5.4% 5.9%
Age, height, and weight are given as mean (SD) values. n = number of patients, m =
male, f =female. Blood pressure drop = > 25% reduction from preoperative mean
arterial blood pressure within 5 min of the hip cementation.
As can be depicted from figure 1, VAS pain scores were below 3 in the
postoperative period in all patients in all four groups.
Figure 1, VAS pain scores 
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VAS pain scores during 24 h after surgery given as mean. VAS pain scores =
visual analog scale 0 - 10; with 0 = no pain and 10 = most severe pain.  *p<0.01,
Fisher test.
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The highest VAS score of each individual patient in the 24 h period and
total pain VAS scores [area under the curve (=AUC) of VAS scores in the
24 h period] were highest for group I (figure 2).
Figure 2, Pain scores and morphine use
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7
Pain scores and morphine use. Highest VAS = highest individual
VAS pain score during 24 h postoperative. AUC = area under the
curve represents total VAS pain scores in the 24 h postoperative
period. ** = statistical difference between group IV versus other
group I and II, p<0.0001. Morphine PCA = dose of morphine in
mg used in 24 hours after surgery by PCA pump.
These higher VAS scores were associated with a significantly higher
consumption of systemic morphine in group I. The mean use of systemic
morphine administered by the PCA infusion pump was in group I to IV,
respectively: 23.7 mg, 17.8 mg, 10.9 mg and 9.9 mg (group I different from
III and IV: p<0.01). Figure 3 shows the incidences of side effects in group
I, II, III, and IV respectively. The incidences of PONV and urinary
retention were not different among groups I, II, III and IV, nor was the
consumption of antiemetics. The mean number of antiemetics used in all
patients was 1.2 (1.1) , 1.2 (1.3) ,  1.1 (1.2) and 1.3 (1.2) in groups I to IV,
respectively. PONV occurred at a higher overall incidence during the first
24 h after surgery in women than men (incidence in women vs. men 77 and
44%, respectively; p < 0.05).
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Figure 3, Incidence of side effects
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A respiratory rate below 10 breaths per min did not occur in any patient.
Arterial oxygen saturation was monitored continuously. The incidence of
desaturations below 90% is summarized in figure 3. The SpO2 of all these
patients increased when oxygen was administered (3 liter per minute by
nasal catheter). Arterial blood gases sampled at such desaturations below 90
% did not show acidosis.
The incidence of itching was dose related as was the incidence of request
for antipruritic medication.
Heart rates decreased 6 to 16 % in all groups after anesthesia, returning to
baseline levels 12 h postoperatively. The incidence of hypotension  was
48.6%, 56.8%, 54.0% and 73.5% of the patients (p<0.05, between group III
and IV) in groups I to IV respectively.
Discussion
The major finding of this study is that the optimum dose of intrathecal
morphine after total hip surgery is as low as 0.1 mg (group III). This dose
resulted in excellent pain relief and a low demand for systemic morphine in
the first 24 h after surgery. The higher dose of 0.2 mg intrathecal morphine
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did not produce better analgesia, and the incidence of itching was higher
and the degree of hypotension more profound and longer lasting.
Intrathecal morphine doses below 0.1 mg  were less effective.
Many studies have evaluated effects of intrathecal morphine for
postoperative pain relief after surgery (Domsky 1992, Kalso 1983, Grace
1996, Reat 1989). These studies (Grace 1996, Reat 1989,  Jacobson 1988)
used higher doses of morphine (up to 2.5 mg) or included patients
undergoing different types surgery (Jacobson 1988). In our study the site
and type of surgery was restricted to total hip replacement surgery.
Adequacy of morphine is reflected by VAS scores and systemic morphine
demand from a PCA pump. After the 0.1 mg intrathecal morphine dose
postoperative pain was effectively relieved during the first 24 h.
PONV showed similar overall incidences in all groups. In this study we
confirm the high incidence of PONV after orthopedic surgery (Weber 1998,
Carpenter 1992). Again PONV was not induced by these low doses of
intrathecal morphine as found in our earlier study (Carpenter 1992).
A major concern with intrathecal morphine is respiratory depression.
Intrathecal morphine has been shown to cause significant dose-related
decreases in SpO2 in human volunteers after doses of 0.2 – 0.6 mg (Bailey
1993). The time to depression of the slope of the ventilatory response to
carbon dioxide curve show peak respiratory depressant effects following
lumbar intrathecal morphine administration that concur with the moment
of highest cervical cerebrospinal fluid concentrations found in another study
(Max 1985, Payne 1985): i.e. at approximately four to five h after injection.
After the lowest dose evaluated in this study (0.2 mg) mild respiratory
depression effects were found in laboratory conditions (Bailey 1993).
Whether similar changes in respiration were present in our clinical study is
unclear. Likewise, others have failed to identify signs of respiratory
depression in clinical conditions, provided that the intrathecal dose of
morphine is restricted to doses less than 0.15 mg (Yamaguchi 1990). The
inability to correlate such mild respiratory depressant effects with low
intrathecal doses of morphine may well relate to the fact that a decrease in
SpO2 is a common phenomenon in elderly patients following both general
and intrathecal anesthesia (Brown 1994). Also, not only intrathecal
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morphine but a whole array of anesthetic drugs can contribute to respiratory
depression. In a recent study eight cases of serious respiratory depression
were detected from the charts of approximately 1600 patients who received
systemic morphine by PCA (Etches 1994). Our elderly patients were
premedicated and sedated with midazolam, intravenous morphine was
administered by PCA pump and systemic antiemetic drugs (droperidol
and/or metoclopramide) were used in the postoperative period. Yet, the
magnitude and incidence of decreases in oxygen saturation were similar to
those reported in another postoperative study in elderly patients not
exposed to intrathecal morphine (Brown 1994).  The key question is
whether respiration after a total hip procedure is affected to a greater extent
when intrathecal morphine is used than when it is left out. We point out
that the mild respiratory depressant effects after 0.2 mg morphine
intrathecally, represent an effect at a dose twice as large as the one that we
defined as the optimum one. Also, any anesthesia technique affects
respiration, and you can always argue that very large numbers of patients
need to be studied to be sure that no respiratory depression after an
intrathecal dose of 0.1 mg morphine. In our view monitoring in intensive
care units is not required because of the administration of 0.1 mg intrathecal
morphine, even in the opiate naive, elderly patient.
Another dose related intrathecal morphine side effect is itching, but it is
easy to manage with a single dose of promethazine when necessary.
Patients in all groups showed, as expected, a decrease of heart rate and
blood pressure after intrathecal anesthesia with bupivacaine and morphine
use (Carpenter 1992). Only one patient in group I (the lowest dose of
intrathecal morphine) had bradycardia. The blood pressure drop after 0.2
mg intrathecal morphine was more profound and longer lasting. In our
earlier study (Weber 1998) we found that 16% of the patients developed
bradycardia when the effect of intrathecal bupivacaine without morphine
subsided in the postoperative period.
In summary, the intrathecal dose of 0.1 mg morphine added to bupivacaine
gives excellent post-operative analgesia for total hip surgery. The earlier
used higher doses of intrathecal morphine (Kalso 1983, Reay 1989,
Jacobson 1988) (> 0.2 mg up to 2.5 mg) were more effective and can cause
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unnecessary and dangerous side effects. In our view 0.1 mg intrathecal
morphine added to bupivacaine provides excellent postoperative analgesia
in the first 24-h, assists in hemodynamic stability, and will not cause
significant respiratory depression. Finally, after this intrathecal morphine
dose, there appears to be no need for routine intensive care-based recovery,
even in elderly patients.
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Chapter 4
The intensity of preoperative pain is directly correlated
with the amount of morphine needed for postoperative
analgesia
This study has been published:
The intensity of preoperative pain is directly correlated with the amount of
morphine needed for postoperative analgesia. R. Slappendel, E.W.G.
Weber, M.L.T. Bugter, R. Dirksen. Anesth. Analg. 1999; 88 (1): 146-8.
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The intensity of preoperative pain is directly correlated
with the amount of morphine needed for postoperative
analgesia
Introduction
Studies have shown that severe postoperative pain can influence patient
outcome after surgery (Jamison 1993, Ready 1996). Undertreatment of pain
may impede short-term recovery and may even have a detrimental long-
term effect on health (Liebeskind 1991, Jänig 1994). Appropriate pain
management for postoperative patients contributes to earlier mobilization,
shortened hospital stay, and reduced costs (ASA 1995). Preclinical studies in
experimental animals suggest that preemptive analgesia might improve the
quality of postoperative pain management (Brennan 1997). Although the
beneficial effects of preemptive analgesia are less evident clinically (Collis
1995), severe pain syndromes, such as phantom limb pain may be reduced
or even prevented by preemptive epidural blockade (Wall 1988). Thus, we
may consider that preoperative pain can give rise to postoperative problems.
The aim of this study was to examine whether the severity of preoperative
pain is related to postoperative pain levels and morphine intake in patients
undergoing first hip replacement.
Methods
The ethical committee of our hospital approved the study. Sixty consecutive
patients suffering from osteoarthritis of the hip scheduled for first total hip
surgery were included. Preoperative Visual Analog Scale (VAS) scores and
analgesics were assessed one day before surgery. Three groups of patients
were recognized: patients with mild pain (VAS score between 0 to 4),
moderate pain (VAS score from 4 to 7), or severe pain (VAS score from 7
to 10).
All patients started a non-steroid antiinflammatory drug, nabumetone 2000
mg on the day of surgery, and continued this dosage for at least three
postoperative days. All patients were premedicated with midazolam 5, 7.5,
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or 10 mg (i.e. ± 0.1 mg/kg) orally one h before spinal anesthesia. All
patients received intrathecal anesthesia with bupivacaine 20 mg and 0.1 mg
morphine dissolved in 4 mL. At the patient’s request further sedation was
given using midazolam: 1 mg every 5 min until the desired level of sedation
was achieved. In the postoperative period pain was treated with oral
nabumeton 2000 mg once a day, starting on the day of surgery. A patient
controlled analgesia (PCA) pump was connected immediately after surgery
and set at the baseline infusion rate of 0.5 mg morphine/h, with bolus
dosage 1 mg morphine at a minimum interval of 5 min.
Non-invasive blood pressure, electrocardiogram, transcutaneous oxygen
saturation, and respiratory frequency were continuously monitored during
anesthesia and in the intensive care unit during the first 24 h after surgery.
All postoperative side effects; pain (VAS scores), postoperative nausea and
vomiting, itching, urinary retention (> 400 mL), hypotension (decrease of
mean arterial blood pressure to below 80% of its preoperative value) were
registered during 3-h observation periods, as was the amount of morphine
consumption by PCA pump.
Statistical analysis was performed using ANOVA, followed by Newman-
Keuls post-hoc analysis when appropriate. P value less than 0.05 was
considered as significant. Data are expressed as mean ± SD.
Results
Two patients were excluded from the study because their postoperative
records were not complete. The group with pre-operative mild pain
consisted of 12 patients, the group with moderate pain 18 patients, and the
group with severe pain 28 patients.
Age, weight, height and preoperative intake of non-steroid anti-
inflammatory drugs were not different among the three groups (Table 1).
None of the patients used narcotics preoperatively. The incidence of
postoperative side effects, nausea and vomiting, urinary retention, and
itching showed no differences between groups. Respiratory depression did
not occur in any patient.
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Table 1. Demographic data
Mild preoperative
pain (n=12)
Moderate
preoperative pain
(n=18)
Severe preoperative
pain (n=28)
Gender M/F 1 / 11 2 / 16 7  / 21
Age (years)     62 (±10)   67 (±8)     62 (±11)
Height (cm) 168 (±8) 168 (±7) 168 (±7)
Weight (kg)    76 (±13)     69 (±12)     74 (±12)
NSAID use 40% 39% 40%
n = number of patients, M = male, F = female. Standard deviation between
parentheses. No differences between groups.
Excellent pain relief in the postoperative period was achieved in all groups
(Figure 1). There were no differences between groups in VAS scores in any
of the 3-h observation periods. Likewise the total VAS scores were not
different. The morphine intake during the first 24 hours was different
among three groups (ANOVA: F (2.55) = 4.54, p=0.015), and post hoc
analysis showed the highest intake by patients in the severe pain group. The
mean morphine intake was 19.2 mg (SD ± 8.3) in the mild pain group, 21.2
mg (SD ± 12.1) in the moderate pain group, and 29.5 mg morphine (SD ±
12.6) in the severe pain group in the first 24 h postoperatively (figure 2).
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Figure 1. Post-operative pain scores
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Figure 2. Morphine by PCA pump
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Discussion
This study shows, that patients with severe preoperative pain need an
approximately 50 % higher morphine intake by PCA pump to attain the
same level of postoperative analgesia in first 24 h after total hip surgery,
than patients with mild or moderate preoperative pain. It also shows that
patients want to lower their pain scores to the same range regardless of
where these scores started from preoperatively.
Pain is an extremely complex process that involves the interaction of an
array of neurotransmitters and neuromodulators at all levels of the neuraxis
(Siddall 1997, Dirksen 1991, Willis 1991). A long duration of severe pain
may change the processing of pain, for instance by involving pain memory
and/or neuroplastic changes (Dirksen 1991, Neugebauer 1990).
Identification of various receptors and processes that are involved in the
transmission of pain at the spinal level, has led to the use of new agents and
techniques in pain management (Siddal 1997). These include the use of
preemptive analgesia and techniques such as intrathecal drug administration
and epidural spinal cord stimulation (Siddall 1997, Coli 1993, Katz 1992).
For example, the preoperative administration of sodium naproxen or
intravenous morphine significantly reduces the analgesic requirements in the
postoperative period (Coli 1993). Preemptive epidural morphine was found
to be superior to epidural morphine given postoperatively for pain relief
after lumbar laminectomy (Kundra 1997). Pre- or post incision
administration of either intrathecal morphine or bupivacaine reduced
hyperalgesia on the day of surgery (Brennan 1997). In our study all of these
measures were included to minimize postoperative pain and postoperative
morphine requirements: i.e. administration of nabumeton preoperatively,
and presurgical intrathecal administration of bupivacaine and morphine.
The relationship between preoperative pain level and postoperative
morphine intake indicates that preoperative assessment of pain in an
individual patient allows anticipation of the patient’s needs; this can lead to
better postoperative pain relief.
Our data contrast with those of a recent study on major joint surgery, where
no such relationship was found (Jamison 1997). However, in their study five
types of orthopedic surgery were included (total hip arthoplasty, total knee
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arthroplasty, total hip revision, total knee revision and total knee bilateral),
and as well as various preoperative diagnoses (osteoarthritis, rheumatoid
arthritis, degenerative joint disease, avascular necrosis, juvenile rheumatoid
arthritis and “other”). It is clear that differences in type of surgery and
underlying diagnosis could affect the degree of postoperative pain. Further,
their analysis consisted only of a questionnaire dealing with patient
satisfaction filled in on the day of discharge.
In our view, severe chronic pain syndromes need specific attention by the
anesthesiologist and other medical attendants. Preemptive analgesia in
patients with severe chronic pain was found effective to avoid the
postoperative pain problem of phantom limb (Wall 1988). Our study shows
that perseverance of pain occurs in cases of the more common pain
syndromes like osteoarthritis of the hip as well. To improve the quality of
postoperative pain control, one may consider starting analgesic treatment in
the preoperative period. We consider whether such improvement can be
achieved by simple measures, e.g.: by doing total hip surgery in an earlier
phase when pain is not yet severe; by extended pretreatment with non
steroidal anti-inflammatory drugs, or by administration of a higher
preoperative dose of intrathecal morphine. Perhaps specific attention to this
aspect of the total hip procedure may improve the outcome.
Chapter 4
44
Intensity of preoperative pain
45
Chapter 5
Intrathecal addition of morphine to bupivacaine is not the
cause of postoperative nausea or vomiting
This study has been published:
Bijeffecten van intrathecaal morfine. R. Slappendel, E.W.G. Weber, R.
Dirksen, M.J.M. Gielen. Nederlands tijdschrift voor Anesthesiologie. 1997;
10: 1-6.
and:
Intrathecal addition of morphine to bupivacaine is not the cause of
postoperative nausea or vomiting. Weber EWG, Slappendel R, Gielen MJM,
Dirksen R. Reg Anesth  Pain Med 1998; 23 (1): 81-86.
and:
Intrathecal addition of morphine to bupivacaine. Letter to the editor. Weber
EWG, Slappendel R, Gielen MJM, Dirksen R. Reg. Anesth. Pain Med. 1999;
24 (1): 94-95.
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Intrathecal addition of morphine to bupivacaine is not the
cause of postoperative nausea or vomiting
Introduction
Spinal opiates are frequently used for postoperative pain control in major
orthopedic surgery of the lower limb (Törn 1994, Knudsen 1994, Kalso
1983). In our clinic, the intrathecal combination of a local anesthetic plus an
opiate serves as an easy and cheap anesthetic technique which produces
both excellent surgical conditions and excellent post operative pain relief.
Moreover, the patients can ambulate quickly after surgery once the effect of
the local anesthetic has worn off, as opiates do not impair motor function.
Despite the advantages of spinal opiates, bothersome side effects were
described and these include respiratory depression, urinary retention,
postoperative nausea and vomiting (PONV) and pruritis. The (late)
respiratory depression causes concern, because it is hazardeous. However, it
is extremely rare when small doses of intrathecal morphine are used (< 0.3
mg). In contrast, nausea and vomiting occur far more frequently in the
postoperative period. These two bothersome side effects are attributed to
the intrathecal use of opiates and not to local anesthetics (Morgan 1989,
Yaksh 1981, Quinn 1994), although either symptom does occur in the
absence of intrathecal opiates as well.
We had two questions. First, to which extent do intrathecal opiates cause or
contribute to PONV? Therefore, we investigated the relationship of PONV
and intrathecal opiate by comparing the incidence of PONV after
intrathecal bupivacaine to the incidence of PONV after bupivacaine plus
morphine. Metoclopramide was found to reduce PONV after intrathecal
anesthesia in orthopedic patients (Spelina 1984). The second question
relates to the use of metoclopramide for treatment of PONV:  how
effectively can the drug reduce the incidence of PONV after intrathecal
morphine.
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Methods
The study was approved by the ethical committee of our hospital and
informed consent was obtained from all patients. Four hundred consecutive
patients scheduled for major orthopedic surgery of the lower limb by
intrathecal anesthesia were included in the study after an informed consent.
All patients were premedicated with approximately 0.1 mg/kg midazolam
(that is 5, 7.5, or 10 mg) orally one hour before spinal anesthesia. Patients
were allocated to three groups. Group I consisted of the first 200
consecutive patients. Spinal anesthesia was produced in each of these
patients by administering 20 mg bupivacaine plus 0.2 mg morphine solved
in 4 mL, intrathecally. Group II consisted of the next 100 patients and
spinal anesthesia was produced in the same way: by administering 20 mg
bupivacaine and 0.2 mg morphine solved in 4 mL. In addition, each of
patient of group II was treated with metoclopramide 20 mg intramuscularly
after settlement of anesthesia and a second dose of 20 mg metoclopramide
was administered intramuscularly after arrival at the recovery room. Finally,
group III consisted of the next 100 patients. Spinal anesthesia was produced
by the intrathecal administration of 20 mg bupivacaine only.
Adequate sedation was provided to each patient during the procedure: the
anesthesiologist administered 1 mg midazolam at the minimum interval of 5
minutes untill the patient indicated that the desired sedation was settled.
Non-invasive blood pressure, heart frequency (ECG), SpO2, and respiratory
frequency were continuously monitored during anesthesia and at the
intensive care unit during the first 24 hours after surgery.
Pain: In the post-operative period, all patients were treated with the
analgetic diclofenac 2 mg/kg orally, 3 doses a day. If diclofenac was contra-
indicated oral paracetamol was given (50 mg/kg, 4 times a day). Pain was
scored using VAS scores (0 - 10; with 0 = no pain). If pain was present
(VAS score>3) morphine 0.14 mg/ kg was administered intramuscularly to
a maximum of 6 times 10 mg per day.
Chapter 5
48
Postoperative nausea and vomiting (PONV) was treated according to the
standard scheme (figure 1). Each sequential step was adapted at the interval
of 1 hour. Step 1 was the administration of 10 mg metoclopramide
intramuscularly. When PONV persisted or recurred, the same dose of
metoclopramide was administered i.m.. If PONV still persisted, 1.25 mg
droperidol was given intravenously. Finally, if step 1 through 3 had not
reduced PONV satisfactory then 5 mg tropisetron was given intravenously
(step 4; figure I). Postoperative nausea and vomiting was evaluated from: 1.
the patient’s subjective feeling (the presence or absence of subjective nausea
or actual vomiting was noted at the interval of 3 hours during 24 hours
postoperatively); 2. the patient’s request to be treated with an anti-emetic;
and, 3. the actual consumption of antiemetics used.
Figure 1. Standardized treatment of postoperative nausea and vomiting with
antiemetics during 24 hours after surgery.
first step: 10 mg metoclopramide intramuscular
second step: 10 mg metoclopramide intramuscular
third step: 1.25 mg droperidol intravenous
fourth (final) step: 5 mg tropisetron intravenous
Each step was started by patient’s request. The minimum interval between each
step was one hour.
Other side effects scored in the postoperative period included itching,
urinary retention (defined as absence of spontaneous voidance of urine at 7
hours after surgery and the bladder content at catheterisation of > 400 mL),
hypotension (> 20% reduction of preoperative mean arterial blood
pressures), and bradycardia (heart rate below 40 beats per minute). The
presence or absence of these side effects was noted at a 3 hourly interval
during the 24 hour observation period. Also, the medication for treatment
of these side effects was registered at the same interval during the 24 hour
observation period.
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Statistical analysis
Pain scores were analyzed using a one way ANOVA followed by Scheffé ‘s
post hoc analysis. The incidence of PONV was analyzed by Fisher's exact
test. P value less than 0.05 was considered as significant.
Results
Demographic data and the incidence of side effects are given in table I. The
three groups did not differ for age, gender, and peroperative blood loss.
Type and duration of the surgical procedures at the lower limb were similar
for the three groups.
Table 1. Demographic data and side effects
Group I Group II Group III
n 200 100 100
intrathecal bupivacaine 20 mg 20 mg 20 mg
intrathecal morphine 0.2 mg 0.2 mg -
intramuscular metoclopramide - 40 mg -
mean age (SD) in years 64.5 (11.1) 65.5 (12.5) 66.6 (10.9)
site of operation (knee/hip %) 24.5% / 75.5% 30% / 70% 17%/83%
Itching % 51.5% 53% 3%*
Urinary retention % (> 400
mL)
63.8% 64.3% 78.6%
Hypotension 42% 40% 35%
Bradycardia 0% 0% 16%*
n = number of patients *=P<0.001. Further explanation see text.
Pain
As can be depicted from the VAS scores given in table 2 excellent pain
relief was present in the post operative period for all patients in group I and
II. Highest pain VAS scores (i.e. comparing the highest VAS score of each
individual patient in the 24 hour period) and total pain VAS scores (area
under the curve (=AUC) of VAS scores in the 24 hour period) were highest
for group III. Highest VAS scores: F (2.396) = 32.92, p< 0.001; Scheffé’s
post hoc: group III different from group I and II, and AUC VAS scores: F
(2.396) =54.14, p<0.001; Scheffé’s post hoc: group III different from group
I and II (see Table 2).
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Table 2. Mean VAS pain scores during 24 hours after surgery
hours after
surgery
3 6 9 12 15 18 21 24 HV AUC
Group I 0.05
(0.35)
0.31
(1,32)
0.73
(1,63)
0.81
(1.54)
0.66
(1.53)
0.72
(1.62)
0.66
(1.39)
0.71
(1.39)
1.8
(0.2)
11.5
(1.2)
Group II 0.05
(0.29)
0.38
(1.13)
0.77
(1.51)
0.82
(1.54)
0.80
(1.65)
0.40
(1.21)
0.66
(1.52)
0.51
(1.17)
1.6
(0.2)
11.7
(2.0)
Group III 0.49**
(1.24)
2.14**
(2.27)
2.52**
(2.19)
2.27**
(1.98)
1.95**
(1.84)
0.86
(1.21)
1.03**
(1.27)
1.61**
(1.74)
3.8*
(0.2)
35.5*
(2.4)
Standard deviation between arrows. HV = mean of highest individual VAS scores
during 24 hours postoperative. AUC = area under the curve of VAS scores in the 24
hour period postoperative.  * = statistical difference between group III versus group I,
and II, p<0.0001. ** = statistical difference between group III versus group I, and II,
p<0.001. Further explanation see text.
These higher VAS scores occurred even though a relevantly and
significantly higher consumption of systemic morphine was noted for
patients treated with bupivacaine alone (group III) compared to those of
group I and II (bupivacaine plus morphine).
Postoperative nausea and vomiting (PONV)
Patients subjective feeling every 3 hours postoperatively showed no
statistical differences between groups.  The maximum PONV percentages
were 41.1%, 32.7% and 37%  respectively,  which all were reached 9 hours
after surgery (Figure 2, Table 3). The consumption of antiemetics was
similar in all groups. The number of patients who needed one or more
antiemetics during the first 24 hours after surgery was 112 (56.6%), 57
(58%) and 60 (60%) in group I, II and III respectively. The mean number of
antiemetics used in all patients was 1.1 (SD 0.97) , 1.1 (SD 0.86) ,  and 1.2
(SD 1.06) , in group I, II, and III respectively. The mean number of
antiemetics used in patients with PONV was 1.9,  1.9, and 2.0 respectively.
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Figure 2. PONV percentage
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Table 3. PONV percentages during 24 hours after surgery
hours after
surgery
3 6 9 12 15 18 21 24
Group I 11.7% 26.4% 41.1% 28.3% 20.4% 12.1% 9.2% 8.2%
Group II 12.0% 29.3% 32.7% 32.0% 21.1% 15.2% 14.5% 11.1%
Group III 7.0% 24.0% 37.0% 25.0% 21.6% 11.6% 20.5% 22.6%
Patient’s subjective feeling of PONV every 3 hours postoperatively
Other side effects:
Itching mainly occurred in patients treated with intrathecal morphine: the
incidence was 51.5% (group I) and 53% (group II), in contrast to only 3%
in group III (p<0.001). The incidence of urinary retention (defined as
absence of spontaneous voidance of urine at 7 hours after surgery and the
bladder content at catheterisation of > 400 mL) was 63.8%, 64.3% and
78.6% in group I,II and III respectively. Hypotension (defined as decrease
> 20% from base line level)  was present in 42%, 40% and 35% in groups
I,II and III respectively. As can be depicted from table I, bradycardia (heart
rate below 40 bpm) presented in group III only, and had the incidence of
16%, which seemed statistically different (p<0.001).  Typically, bradycardia
presented in the very same period that motor function recovered.
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Discussion
The main finding of this study is that the incidence of postoperative nausea
and vomiting was not different for the three groups of patients. This means
that the notion that intrathecal morphine is a main cause for postoperative
nausea and vomiting is not valid. Also, the present mode for treatment of
PONV is without effect. These findings and outcome of three modes of
anesthetic treatment of patients subjected to major orthopedic surgery of
the lower limb are discussed further.
This study confirms the combined administration of intrathecal morphine
and bupivacaine that results in excellent surgical conditions, also produces
excellent postoperative pain relief during at least 24 hours. However the
only side effect definitely caused by intrathecal morphine is itching which is
easy to treat.
In earlier studies (Törn 1994, Knudsen 1994, Kalso 1983, Morgan 1989) the
incidence of PONV after intrathecal morphine in major orthopedic surgery
was between 50% and 65%. We confirm the generally high incidence of
PONV that proved especially high after orthopedic surgery (Quinn 1994) in
all  our groups. In their reports, the various authors seemed to imply that it
is the intrathecal morphine that caused PONV. Our study shows no
relationship between the use of intrathecal morphine and the hight of the
incidence of PONV, even though postoperative nausea and vomiting
occurred in high frequencies in all our groups and the incidence was equal
to above mentioned studies. Therefore, we propose that intrathecal
morphine did not attribute to PONV.
In a study of Carpenter  (Carpenter 1992) a lot of possible variables were
able to influence the development of PONV. The variables gender, height,
hypertension, history of carsickness, base line heart rate, position for spinal
puncture, type of local anesthetic, dose of anesthetic, were able to influence
PONV, but were kept all constant in our study. The highest frequency
PONV occurred 9 hours after surgery, which can be an argument that
intrathecal medicaments caused PONV. Regarding our results PONV was
not induced by intrathecal morphine, and was more likely due to type and
dose of local anesthetic.
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Low dosages of metoclopramide are ineffective to reduce PONV after
intrathecal anesthesia in orthopedic patients (Spelina 1984). In the higher
dosages we used metoclopramide it was not effective to treat PONV, in
contrast to the study of  Knudsen et al (Knudsen 1994).  They found a
reduction in the incidence of PONV from 58% to 17% after 40 mg
metoclopramide intramuscularly. However the presence of PONV was
recorded up to five hours after surgery. The anti-emetic properties of
metoclopramide result centrally from its blockade of dopamine receptors of
the chemoreceptor trigger zone, in higher doses antagonism of the central
5-HT3 -receptors and peripherally from its stimulation of gastric and small
bowel motility, thereby preventing the gastric stasis and dilation that are part
of the vomiting reflex (Schulze-Delrieu 1981). However, it is not expected
that intrathecal morphine or bupivacaine cause a decrease in gastric or small
bowel motility. So it can be concluded that central action of
metoclopramide (antagonism of dopamine and 5-HT3 -receptor) did not
reduce PONV after intrathecal morphine or bupivacaine. Besides dopamine
and 5 HT3 -receptors, muscarinic cholinergic and histamine receptors play a
role in mediating the emetic response Watch 1992). Recently one study
(Moscovici 1995) and one correspondence (Ramaioli 1996) suggested that
central administration of anticholinergic drugs indeed reduce PONV, after
epidural or intrathecal anesthesia with bupivacaine and morphine. Thus, we
consider whether another type of local anesthetic, a lower dose of
intrathecal local anesthetic, lower peak block heights, or centrally
administered cholinergic drugs can help to produce the lower incidence of
PONV.
In conclusion, intrathecal morphine added to bupivacaine is superior to
intrathecal bupivacaine alone for major orthopedic surgery. It is a cost
effective technique that minimizes the use of analgesics and disposables in
the per- and postoperative period. Also, there is no need for catheters,
infusion pumps or PCA pumps. Moreover, the excellent post-operative
analgesia and hemodynamic stability are arguments to choose this anesthetic
technique. Despite these benefits, one has to cope with some at times
bothersome side effects. This study focussed the side effect postoperative
nausea and vomiting. There is ample reason to relate PONV and 0.2 mg
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intrathecal morphine. Also, present treatment of PONV proved
unsatisfactory and difficult.
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Chapter 6
Itching after intrathecal morphine
Incidence and treatment
This study has been submitted to the European Journal of Anesthesiology.
Robert Slappendel , Eric W.G. Weber, Bart Benraad, Jacques van Limbeek,
Ris Dirksen.
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Itching after intrathecal morphine
Incidence and treatment
Introduction
Intrathecal opiates are often used for postoperative pain control in major
orthopedic surgery of the lower limb (Domsky 1992, Kalso 1983, Grace
1996, Reay 1989). In our clinic, the intrathecal combination of a local
anaesthetic and an opiate serves as an easy and cheap anaesthetic technique
which produces both excellent surgical conditions and excellent post
operative pain relief. Moreover, the patients can ambulate quickly after
surgery once the effect of the local anaesthetic has worn off, as opiates do
not impair motor function.
Earlier studies used intrathecal morphine in doses up to 2.5 mg morphine, and
many side effects were reported, including the dangerous late respiratory
depression (Reay 1989, Jacobson 1988) and the more harmless but at times
extremely bothersome side effects of postoperative nausea and vomiting,
urinary retention and itching. The incidence of post operative nausea and
vomiting, or urinary retention were unrelated to intrathecal morphine when
doses of 0.2 mg are used (Weber 1998). In this study we evaluated whether the
incidence and severity of itching can be minimised by adapting the low dose
range of intrathecal morphine. Our questions were: 1) is itching a dose
dependent phenomenon and is its incidence less after the lower doses of the
range of 0.025 – 0.2 mg morphine intrathecally; 2) does systemically
administered morphine contribute to the problem of itching; and, 3) how well
can we control itching caused by low doses of intrathecal morphine by
applying a standardised treatment using promethazine and - for intractable
itch - naloxon.
Methods
The study was approved by the ethical committee of our hospital and
written informed consent was obtained from all patients.  Finally hundred
forty three consecutive patients scheduled for total hip surgery by
intrathecal anesthesia were included in the study after an informed consent.
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All patients were premedicated with 5, 7.5, or 10 mg midazolam
(approximately 0.1 mg/kg) orally one hour before intrathecal anesthesia.
Intrathecal anesthesia was produced in each of these patients by
administering 20 mg bupivacaine plus morphine solved in 4 mL,
intrathecally. Intrathecal puncture was performed in a sitting position.
Patients were allocated and randomized to four groups in a double blind
manner: Group I,  0.025 mg (0.00625 mg/mL), Group II, 0.05 mg (0.0125
mg/mL), Group III, 0.1 mg (0.025 mg/mL) and Group IV, 0.2 mg (0.05
mg/mL) morphine. The morphine dose was only known to the pharmacist.
Adequate sedation was provided at patient request during the procedure: the
anaesthesiologist administered 1 mg midazolam at the minimum interval of
5 minutes until the patient indicated that the desired sedation was settled.
Non-invasive blood pressure, heart frequency (ECG), SpO2, and respiratory
frequency were continuously monitored during anesthesia and at the
intensive care unit during the first 24 h after surgery.
Itching In the postoperative period the presence of itching, and treatment
for itching were noted every 3 hours by nurses at the intensive care ward.
Itching was treated by a standardised protocol. In brief, the need for relief
of itching was indicated by the patient. Thus, only on request of the patient,
treatment of itching was initiated with a first dose of 25 mg promethazine
intramuscularly. If itching had not diminished within 1 hour after this
intramuscular injection, 0.12 mg naloxon was given subcutaneously. If
itching diminished but returned after a period longer than one hour,
intramuscular injection with promethazine was repeated once. If itching did
not diminish after an subcutanous injection of naloxon an continuous
intravenous drip with naloxon was started at 5 mg/kg/h. The severity of
itching was estimated from the requirement of treatment, and we recognised
three categories: mild = only present after inquiry, moderate = need for
promethazine, severe = need for naloxon.
Pain: In the post-operative period, all patients were treated with the
analgesic nabumeton 30 mg/kg orally, 1 dose a day (1000 mg, 1500 mg or
2000 mg). Pain was evaluated using VAS scores (0 - 10; with 0 = no pain). If
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pain was present morphine was administered intravenously in a patient
controlled manner. The settings of the PCA (patient controlled analgesia)
pump (BRAUN®, Melsungen, Germany): baseline 0.0 mg/hour, bolus dose
1.0 mg, bolus interval 5 minutes, maximum 30.0 mg per 4 hours.
Other side effects. The presence or absence of other side effects (post
operative nausea and vomiting (= PONV), urinary retention, sedation) was
noted at a 3 h interval during the 24 h observation period. Also, medication
to treat these side effects were registered at the same interval during the 24
h observation period.
Statistical analysis Pain scores were analysed using a one way ANOVA
followed by Scheffé ‘s post hoc analysis. The incidence of PONV was
analysed by Fisher's exact test. P value less than 0.05 was considered
significant. Incidences of and the severity of itching was analysed by chi-
sqaure tests. The adjusted standardized residuals indicate the contribution of
each cell of the table to the significance of the purposed differences. The
duration of itching was calculated and analyzed by means of an anova with a
Scheffé ‘s post hoc test.
Results
Demographic data are given in table 1. The four groups did not differ for
age, length, weight or gender. Likewise other variables, e.g. preoperative use
of beta blockers, peroperative blood loss, percentages of patient’s which got
sedation during surgery, use of cementation, and blood pressure drop (>
25% decrease in MAP after cementation) showed no differences among the
groups.
Itching Itching occurred in all groups. The overall incidence of itching was
related to intrathecal morphine dose (figure 3) and time after surgery (figure
4). The overall incidences of itching were: 14.3%, 21.6% , 48.6% and 61.7%
in group I, II, III, and IV respectively.
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 Table 1.  Demographic data and intraoperative factors.
Group I II III IV
Intrathecal morphine 0.025 0.05 0.1 0.2
n 35 37 37 34
Age in years 62.6 (12.8) 65.9 (8.9) 61.9 (15.2) 62.9 (11.3)
Length in cm 167.6 (7.8) 169.5 (8.2) 169.7 (7.4) 167.9 (8.6)
Weight in kg 69.5 (11.4) 73.5 (14.1) 74.9 (10.9) 74.2 (13.6)
Gender (m/f) 12/23 10/27 10/27 7/27
Age, length, and weight are given as mean values, standard deviation in
parentheses. n = number of patients, m = number of men, f = number of
female. Standard deviation in parentheses.
 Figure 3. Incidence and severity of itching
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Figure 4. Incidence of itching
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The adjusted standardized residuals indicate a trend over group I to IV
respectivly varying from -3.1, -2.2, 1.8 to 3.3 in favor of itching (chi-square
= 22.74; df = 3; p = 0.00005). The incidence of itching was related to time
after surgery. Highest (time related) incidences of itching were found 6 to 9
hours after surgery (figure 4). The mean duration (hours) of itching in
patients who itched was: 3.6, 3.4, 7.5, and 6.7 in group I, II, III, and IV
respectively. A post hoc comparison between groups revealed that the
duration of  itching only differed between group I and II versus group III
and IV respectively (F = 11.27; df (3,142); p = 0.0000 ). Both the need for
treatment (figure 3) and the mean hours of itching (table 2) increased with
the intrathecal morphine dose.
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Table 2. Mean hours of itching
Group (n) Itching (n) Mean hours
of itching
Total hours
of itching
Group I:
0.025 mg
morphine
35 5 3.6 18
Group II:
0.05 mg
morphine
37 8 3.4 27
Group III:
0.1 mg
morphine
37 18 7.5 135
Group IV:
0.2 mg
morphine
34 21 6.7 141
n = number of patients.
Patients who experienced itching used significantly less systemic morphine
(n = 52; 11.7 (± 11.7) mg morphine) then those patients who did not have
itching at all (n=91; 18.0 mg (± 14.3) morphine, t = 2.71; df = 139; p =
0.008). In our population of patients we found no relation between age,
gender, weight and the incidence of itching.
Pain
As can be depicted from the VAS scores given in figure 5, excellent pain
relief was present in the post operative period for all patients in all groups.
The mean use of systemic morphine administered by PCA infusion pump
was in group I to IV respectively: 23.7 mg; 17.8 mg; 10.9 mg; and, 9.9 mg. A
statistical difference is present between group III and IV versus group I,
p<0.01. No correlation was found between VAS scores and itching.
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Figure 5. VAS pain scores 
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Other side effects
Respiratory depression (defined as breathing frequency below 10 per min
and arterial blood gas showing acidosis and hypercarbia) did not occur in all
groups. Incidences of PONV were 34.3%, 45.9%, 37.8% and 41.2% in
group I, II, III, and IV respectively. The incidence of urinary retention
(defined as absence of spontaneous voidance of urine at 7 hours after
surgery and the bladder content at catheterisation of > 400 mL) was 74.2%,
92.0%, 67.6% and 70.6% in group I, II, III and IV respectively. There were
no differences among the four groups for these two side effects and there
was no correlation between PONV, incidence and degree of sedation or
urinary retention with itching.
Discussion
This study shows clearly, that intrathecal injection of morphine in human
beings results in itching and the incidence of this effect increased in a dose
dependent fashion in the dose range of 0.025 – 0.2 mg intrathecal
morphine. Itching responded well to the antihistaminic drug promethazine
in the dose of 25 mg intramuscularly.
In our study the incidence of itching is found to increase in a dose related
fashion. The incidence of itching after intrathecal morphine in our study
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(14.7 to 61.3%) was similar to that earlier reported in the elderly orthopedic
patient (Jacobson 1988, Weber 1998). The incidence of itching after
intrathecal bupivacaine alone (without added morphine) was 1% in an
earlier study in 100 patients (Weber 1998). Even higher incidences and a
greater intensity of itching were found in young women after elective
caesarean section (Alhashemi 1997, Cardosos 1998, Milner 1996). However,
we have not found a relation between gender or age to the incidence of
itching in the population studied. The incidence of itching was not found to
relate to the dose in the study of Milner who compared 0.1 and 0.2 mg
intrathecal morphine after elective caesarean section (Milner 1996). Yet, our
findings are based on inquiry every three hours, which seems to be the best
way to establish the incidence of itching (Pinckaers 1980, Dirksen 1980).
Highest incidences of itching were found 6 to 9 hours after surgery (figure
IV), i.e. 7.5 to 10.5 hours after intrathecal injection. The kinetics of the
liquor flow (Partain 1978) and the delay between moment of injection and
itch are consistent, which suggests that supraspinal centrally located
morphine receptors mediate itching. In accordance with this notion are data
of animal studies (Thomas 1993, Tohda 1997) which implied opioid
receptors in the medullary dorsal horn in an itch-like phenomenon.
Noteworthy, centrally induced itch is always sensed in the skin, and thereby
itch is caused by systemic administration of morphine. Here, itching has an
incidence of approximately 1% (Weber 1998), and it may relate to
morphine’s ability to cause release of histamine (Hermens 1985).
We do not expect that the administration of an antihistaminic drug is causal
therapy for centrally induced itching. Nevertheless, it was highly successful
in most patients. Only in one patient in group IV 25 mg promethazine was
insufficient on its own and naloxon was needed. Several drugs (e.g.
droperidol, propofol, diphenhydramine) have been used without success in
clinical studies (Alhashemi 1997, Horta 1996, Warwick 1997). Nalbuphine
(Alhashemi 1997) effectively relieved itching by intrathecal morphine, but
resulted in higher pain VAS scores. Ondansetron is only used in case
reports to treat itching (Larijani 1996).
We conclude that even after low doses of intrathecal morphine the
incidence of itching is high and typically dose related to intrathecal
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morphine. When necessary it is easy to treat by administration of
promethazine 25 mg intramuscularly.
Figure 1. Standard operating procedure for the evaluation of itch.
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Figure 2. Flowchart for itch evaluation and the four steps of treatment.
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Chapter 7
Non-invasive measurement of bladder volume as an
indication for bladder catheterization after orthopedic
surgery and its effect on urinary tract infections
This study has been published:
Non-invasive measurement of bladder volume as an indication for bladder
catheterization after orthopedic surgery and its effect on urinary tract
infections. R. Slappendel, E.W.G. Weber. European Journal of
Anaesthesiology 1999; 16: 503-506.
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Non-invasive measurement of bladder volume as an
indication for bladder catheterization after orthopedic
surgery and its effect on urinary tract infections
Introduction
Our hospital specializes in elective orthopedic surgery. In our experience,
the two most common short-term complications are nausea and vomiting
and urinary retention, both of which occur in about 10% of patients. Now
that the volume of the bladder can be measured non-invasively and with
reasonable accuracy by ultrasound (Coombes 1994), we wondered if this
measurement could be used for a more logical approach to the decision to
pass a urinary catheter. We studied the number of urinary catheters used
and number of urinary tract infections in two periods, one before and one
after the introduction of ultrasonic measurement by the BladderScan®.
Materials and Methods
The BladderScan® (Diagnostic Ultrasound Europe B.V., Lage Dijk 14,
3401 RG IJsselstein, The Netherlands) is a small portable instrument (fig.
1), which measures the bladder volume accurately (Coombes, Fuse 1996).
Low energy ultrasound is reflected from the bladder wall and an algorithm
calculates the bladder volume. The BladderScan® is approved by the Food
and Drug Administration (USA) (FDA) and is available clinically in the
USA. A company representative instructed the nurses in the recovery and
intensive care wards on the instruments use (Fig. 2). The instructions
required less than 1 h. Patients were catheterized by nurses in the recovery
and intensive care wards, and by doctors on the general wards. Before the
BladderScan® became available, guidelines for catheterization were pre-
operative incontinence of urine, post-operative incontinence of urine after
spinal or epidural anesthesia, blood loss during surgery of more than 1 liter,
a medical history of prostatic enlargement, abdominal approach for surgery
to the lumbar spine, long-term use of an epidural catheter, no spontaneous
diuresis by 8 h after surgery, or unexplained restlessness. After the
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BladderScan® became available, the guideline about spontaneous diuresis
was modified to no spontaneous diuresis 8 h after surgery combined with a
bladder volume estimated at more than 800 mL.
 The BladderScan® is a small portable instrument of 2.5 kg
The BladderScan® in use, which measures the bladder
volume by ultrasound.
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Bladder volume was measured every 6 h, unless there had been spontaneous
diuresis, if the patient had unexplained restlessness, or there had been no
spontaneous diuresis 8 h after surgery. The benefits of measuring bladder
volume were judged by the quantity of disposables used for catheterization
(sterile gloves, local anaesthetic gel, sterile swabs, urine bags and trays,
disposable syringes, saline solution and sterile drapes) and the incidence of
urinary tract infections. Our supplies department audited the use of
disposables and urinary infections were monitored by the microbiology
laboratory. Neither department was aware of our study. The Wilcoxon
signed rank test (p < 0.05 considered significant) was used to test for
statistical differences between use of catheters and incidence of infections
before and after the introduction of the BladderScan®.
Results
The details of the patients for the two periods under review are shown in
Tables 1 and 2: there were 1920 patients between 1 January 1997 and 30
April 1997,and 2196 patients between 1 May 1997 until 30 September 1997.
Table 1. Patient characteristics
Period before ultrasonic
bladder volume measurement
Period with ultrasonic bladder
volume measurement
Number of patients 1920 2196
Male/Female 38.2%/61.8% 38.0%/62.0%
Age (years) 45.7 (SD ± 17.8) 45.2 (SD ± 19.7)
Anesthesia 62.3% 79.1%
General anesthesia 57% 53.8%
Spinal anesthesia 38.7% 41.2%
Plexus anesthesia 3.8% 5.0%
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Table 2. Type of surgery
Type of surgery %
Period before ultrasonic
bladder volume measurement
Period with ultrasonic
bladder volume measurement
Cervical spine 2.8 3.6
Thoracic spine 1.5 2.4
Lumbar spine 16.5 16.0
Shoulder/upper arm 6.7 7.8
Elbow/forearm 2.1 2.2
Hand/wrist 5.1 4.3
Pelvis/hip 28.3 27.1
Upper leg 1.3 1.3
Knee/lower leg 22.7 23.4
Ankle/foot 13.0 11.9
Total 100 100
No statistical differences.
There were no important differences between the two groups of patients
who gave their consent to participate in the study, which had the approval
of the hospital ethics committee. The nursing staff easily understood the
guidelines for catheterizing the bladder and the BladderScan®, was easy to
use. The need for disposables was halved in the period in which the
BladderScan® was used, and there were fewer urinary tract infections
(Table 3).
Table 3. Results
Period without bladder
volume measurement
Period with bladder
volume measurement
Number of patients 1920 2196
Number of catheters used 602 349
Percentage of patients who
were catheterized
31.4% 15.9%*
Number of urinary tract
infections
18 5*
*= p<0.05.
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Discussion
The likelihood of post-operative urinary retention depends on the type and
duration of surgery, and the type of anesthesia. Longer operations are more
likely to lead to urinary retention, and surgery to the pelvis or lumbar spine
obtunds the micturition reflexes because of the proximity of the peritoneum
(Tetzlaff 1995). Neuraxial blockade (Caudal, epidural or intrathecal
anesthesia) reduces the urge for micturition (Torda 1984). In other studies,
urinary retention increased after major hip and knee surgery, and retention
makes urinary tract infections more likely (Mitchell 1991, McQueen 1992).
In our study, patients in the two study periods were similar. Slightly fewer
patients in the second period underwent surgery without anesthesia, which
might have decreased the risk of urinary retention by a small amount, but
not enough to affect our overall finding. There has been a previous report
suggesting the urinary infection rate can be reduced by using the
BladderScan® (Moore 1997), and in our study there was a statistically
significant decrease in disposables and urinary tract infections after
introducing the BladderScan®. This decrease was not simply because of
better attention to aseptic technique during the second period the risk of
urinary retention has always been a concern in our daily practice. However,
our study cannot answer definitively whether using the BladderScan®
reduces the infection rate, as there are many factors that we have not
studied. These include antibiotic usage, and single in-and-out,
catheterization, neither of which we used. The marked reduction in the use
of disposables necessary for bladder catheterization means that the purchase
costs of a BladderScan® will be recouped within 2 years. This calculation
does not include the price of antibiotics and prolonged hospital stay due to
urinary tract infections. In addition to the cost effectiveness of the
BladderScan®, there was also a reduction in the nurse’s workload and less
inconvenience and discomfort for the patients. We now use the
BladderScan® routinely in the recovery and intensive care wards. We realize
that our study was sequential and not randomized, but we believe there is a
clear benefit from measuring the bladder volume.
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General discussion
In clinical care for surgical patients, the provision of optimal postoperative
pain relief to patients with minimal adverse effects remains one of the most
challenging and difficult tasks for anesthetic teams.
In 1996 we decided that a major effort to improve the quality of
postoperative care was needed, in order to achieve superior patient comfort;
and, to reduce postoperative complications, related to inadequate pain relief.
After reviewing the literature extensively, we selected on practical and
theoretical grounds the method of intrathecal application of opioids plus
local anesthetics.
Choice for single shot intrathecal anesthesia
Practical grounds Theoretical grounds
Fast onset to surgical anesthesia
No additional manpower is needed to assist
in techniqual problems during 24 hours
No need for extensive education of nurses
with a new technique
Low financial costs
Opioids have their effect at the opiate
receptor site, which is located in the
spinal cord.
From data in the literature we were aware of the risk of adverse effects by
intrathecal opioids such as postoperative nausea and vomiting, urinary
retention, pruritus, sedation, respiratory depression. We hypothesized that
the use of very low doses of intrathecal morphine might result in minimal
adverse effects, but we were uncertain whether such low doses would still
offer the desired analgesic effect. In the 5 studies (Chapter 3 to 7) several
aspects related to this analgesic policy were investigated.
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Postoperative pain
Recently a European task group on postoperative pain (Europain 1998) set
the VAS score of 3 (ranging from zero to ten) or higher in resting patients
as a threshold to start active pain control. In our dose finding study
(Chapter 3) we found that an intrathecal dose of 0.1 mg morphine added to
20 mg bupivacaine provide acceptable postoperative pain relief after total
hip replacement surgery according to these standards of the task force.
After this single intrathecal dose injection pain VAS scores were below 3
during 24 hours after surgery (Chapter 3), with only a minimum amount of
supplement systemic morphine (mean 10.9 mg, SD ± 10.4) during the 24
hours period was needed to achieve this effect. In a subsequent study we
demonstrated that the intensity of preoperative joint pain was significantly
correlated with postoperative pain and the postoperative morphine intake
for postoperative analgesia (Chapter 4). The relationship between
preoperative pain level and postoperative morphine intake indicates that
preoperative assessment of pain in an individual patient allows one to
anticipate the patient’s needs. This can lead to better postoperative pain
relief. To improve the quality of postoperative pain control, one may
consider whether it helps to start analgesic treatment in the preoperative
period. Perhaps such improvement can be achieved by some simple
measures, e.g.: by doing total hip surgery in an earlier phase when pain is
not yet severe; by extended pre-treatment with non steroidal anti-
inflammatory drugs, pre-treatment with opioids, or by administration of a
higher preoperative dose of intrathecal morphine. Perhaps specific attention
to this aspect of the total hip procedure may improve the outcome.
Postoperative nausea and vomiting
In the literature the incidence of postoperative nausea and vomiting is
reported to be high following anesthetic techniques using intrathecal local
anesthetics and opioids. Disappointingly in contrast to our hypothesis this
happened to be the case in all our studies in orthopedic patients with
intrathecal morphine (Chapter 3, 4, 5 and 6). More than 60% of the patients
experienced a period of postoperative nausea and vomiting in the first 24
hours after total hip surgery. However the incidence of postoperative
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nausea and vomiting was not related to different dosages of intrathecal
morphine (Chapter 3). Surprisingly, the incidence of postoperative nausea
and vomiting was similar to patients who did not receive intrathecal
morphine at all! (Chapter 5). This implies that a low dose of intrathecal
morphine, which provides excellent pain relief, is not a main cause for
postoperative nausea and vomiting. Unfortunately, the present protocol for
treatment of postoperative nausea and vomiting using metoclopramide was
ineffective and we need studies to improve the treatment of this nasty
complication (Chapter 5).
Itching
Another side effect associated with intrathecal morphine in our orthopedic
patients is itching. In our study itching was found to be a dose dependent
phenomenon. Unfortunately, itching occurs even after low doses (0.025 – 0.2
mg) of intrathecal morphine, which were effective in terms of pain relief
(Chapter 6). After the optimal dose of 0.1 mg intrathecal morphine only 11%
of the patients reported mild itching. Severe itching for which treatment with
naloxon was required was not present in our patients who received 0.1 mg
intrathecal morphine for postoperative pain relief (Chapter 6).
Urinary retention
Urinary retention occurs frequently after surgery and anesthesia and was
unfortunately also found it to be a frequently occurring complication in the
patients who received intrathecal morphine for pain relief. After total hip
surgery, the incidence of urinary retention was found to be 60% and more.
The main finding of our two studies was that the incidence of urinary
retention for patients who received intrathecal bupivacaine with or without
low doses of intrathecal morphine was similar (Chapter 3 and 5). This
implies that a low dose of intrathecal morphine, which provides excellent
pain relief, is not a main cause for urinary retention. In the detection of
urinary retention was causes annoying discomfort and may lead to morbidity
in patients following surgery and intrathecal anesthesia the BladderScan®
was introduced and evaluated in a study. The need for urinary tract
catheterization was reduced by half in the period in which the
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BladderScan® was used, and significantly fewer urinary tract infections were
observed (Chapter 7).
Respiratory depression
It is a major concern that the application of intrathecal morphine can result
in late respiratory depression. Intrathecal morphine has been shown to
cause significant dose-related decreases in SpO2 and alveolar ventilation in
human volunteers after doses of 0.2 – 0.6 mg (Bailey 1993). After the lowest
dose evaluated in this study under laboratory conditions (0.2 mg) mild
respiratory depressant effects were seen (Bailey 1993). In all our clinical
studies performed with low doses of intrathecal morphine 0.025 – 0.2 mg
late respiratory depression was actively met for but it was not observed.
(Chapter 3 to 6). In total the total of 2400 patients that we investigated in
our clinic from 1996 until the end of 1999. In retrospect, no cases of
clinically relevant respiratory depression were detected in any of these
patients who received systemic morphine by PCA at our recovery or
intensive care ward. In our view, routine instrumental monitoring for
postoperative respiratory depression even in the opioid naive elderly patient
is not necessary provided that the intrathecal dose is of 0.1 mg of morphine
or less.
Cardiovascular adverse effects
We did not study cardiovascular adverse effects following intrathecal
morphine extensively. A common experience was that the heart rate might
decrease with 6 to 16 % after anesthesia, returning to baseline levels 12 h
postoperatively. The incidence of hypotension was 48.6% to 73.5%
(Chapter 3). These cardiovascular changes were considered to be
insignificant with respect to outcome. Surprisingly, bradycardia (heart rate
below 40 bpm) presented in patients (incidence 16%) who did not receive
intrathecal morphine (Chapter 5). Typically, this bradycardia presented in
the very same period that motor function recovered and did not occur in
patients who receive intrathecal morphine. It can be explained as a vagal
reaction to postoperative pain when the effect of the spinal blockade ceases.
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Final conclusion
The simplicity of the intrathecal analgesic technique, the resulting excellent
post-operative analgesia and hemodynamic stability were important
arguments to select this anesthetic technique for per- and postoperative pain
relief in our population of orthopedic surgical patients. A dose of 0.1 mg
morphine intrathecally applied was found to result in optimal pain relief.
Despite these benefits, one has to cope at times bothersome adverse effects.
The main - and surprising - finding of our studies was that the incidence of
the most frequently occurring adverse effects: postoperative nausea and
vomiting, and urinary retention was not related to the addition of intrathecal
morphine. Itching was found to be related to the dose of intrathecal
morphine. Itching was mild low after low doses of intrathecal morphine and
late respiratory depression did not occur at the doses studied. We
hypothesized that lowering the dose of intrathecal morphine would lead to
an optimal pain relieving effect with a reduction of adverse effects to an
acceptable level. To a certain extent this was confirmed in our studies, but
further benefit from optimization of dose schemes is not expected.
Therefore, further improvement of the quality of care in pain relief in
orthopedic surgical patients should be sought at in other pain relief
modalities and/or the development of analgesic drugs with better
pharmacodynamic properties for intrathecal application.
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Summary
Chapter 1
Although intrathecal morphine is used to achieve postoperative pain relief
for more than 20 years the primary goal to realize: “selective spinal
analgesia” without adverse effects is still behind the horizon. The optimal
site to administer opioids e.g. morphine is as close as possible to the opiate
receptor site (spinal cord) by the intrathecal route, as it is the place of
effectiveness. To improve the clinical effectiveness of intrathecal morphine
two strategies are proposed: 1. to lower the intrathecal dose of morphine
and thereby reduce the supraspinal adverse effects while maintaining the
analgesic effects; 2. further research to synthesize highly selective endorphin
mimetic drugs with a minimum of side effects.   
Chapter 2
In Chapter 2 the aims of the study are formulated. Following our hypothesis
that the intrathecal route – from the theoretical point of view – would be
the optimal one for administration of morphine to achieve adequate post
postoperative pain relief after major orthopedic surgery of the lower limb
with a low incidence of adverse effects. We hypothesized that low doses of
intrathecal morphine might probably result in similar pain relief scores but
might minimize the incidence of adverse effects.
Chapter 3
This study was designed to determine the optimal intrathecal dose of
morphine in total hip surgery. The optimal intrathecal dose was defined as
the dose, which provides effective analgesia with minimal side effects during
24 h after total hip surgery. Patients (n=143) scheduled for total hip surgery
were randomized to four double-blinded groups with a standardized
bupivacaine dose but different doses of intrathecal morphine: group I, 0.025
mg; group II, 0.05 mg; group III, 0.1 mg; and, group IV, 0.2 mg. Pain
scores, intravenous morphine intake {patient controlled analgesia (PCA)}
and morphine related side effects (respiratory depression, postoperative
nausea and vomiting, itching, urinary retention) were recorded for 24 h after
surgery. Excellent postoperative pain relief was present in all groups. The
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highest pain scores were found in group I. The mean use of systemic
morphine administered by PCA infusion pump was: 23.7 mg, 17.8 mg, 10.9
mg and 9.9 mg, in group I, II, III, and IV, respectively (p<0.01, group III
and IV versus group I). We conclude that 0.1 mg intrathecal morphine is
the optimal dose for pain relief after hip surgery with minimal side effects.
Chapter 4
The aim of this study was to examine whether severity of preoperative pain
intensity is predictive for postoperative pain and morphine consumption.
Sixty consecutive patients scheduled for total hip surgery during intrathecal
anesthesia were studied. Preoperative Visual Analogue Scale (VAS) scores
and analgesic intake was assessed one day before surgery. Three groups of
patients were identified: those with mild pain (n=12, VAS score between 0
to 4), moderate pain (n=18, VAS score from 4 to 7) and severe pain (n=28,
VAS score from 7 to 10). Postoperative pain scores were recorded in the
first 24 h, as well as the amount of morphine delivered by patient controlled
analgesia (PCA) pump. There were no differences between groups in VAS
scores at any time. Severe preoperative pain levels correlated with
significantly higher postoperative morphine intake. The mean morphine
intake during the first 24 h postoperatively was: 19.2 mg in the mild pain
group; 21.2 mg in the moderate pain group, and 29.5 mg in the severe pain
group (p < 0.05 compared to both other groups). We conclude that patients
with severe preoperative pain: a) self medicate to achieve postoperative pain
scores equivalent to those of patients with mild and moderate pain, and b)
require a higher postoperative morphine intake for adequate analgesia than
patients with mild or moderate preoperative pain.
Chapter 5
This study evaluated the questions: firstly, to what extent do spinal opiates
contribute to PONV (post operative nausea and vomiting); and, secondly, how
effectively can metoclopramide reduce the incidence of PONV after
intrathecal administration of morphine. All patients were scheduled to
undergo major joint surgery of the lower limb. The patients were allocated
to three groups. Group I (n=200): intrathecal anesthesia was induced by
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administration of 20 mg bupivacaine and 0.2 mg morphine. Group II
(n=100): intrathecal anesthesia was induced using the same dosages and
drugs for intrathecal anesthesia, but in addition systemic metoclopramide
was injected in two doses of 20 mg. Finally, for patients in group III
(n=100) intrathecal anesthesia was induced by the administration of 20 mg
bupivacaine only.
The maximum PONV percentages were 41.1%, 32.7% and 37% in group I,
II and III respectively. The consumption of antiemetics was similar in all
groups. The number of patients who needed one or more additional
antiemetics during the first 24 hours after surgery was 112 (56.6%), 57
(58%) and 60 (60%) in group I, II and III, respectively.
Administration of metoclopramide did not reduce the overall incidence of
PONV. Our study shows no relationship between the use of 0.2 mg
intrathecal morphine and the incidence of PONV during 24 hours
postoperatively.
Chapter 6
This study was designed to determine whether low doses of intrathecal
morphine still result in itching and it evaluates the outcome of using
standardized treatment with promethazine and - for intractable itch -
naloxon.
Patients (n=143) scheduled for total hip surgery were randomized to four
double-blinded groups with a standardized bupivacaine dose but different
doses of intrathecal morphine: group I, 0.025 mg; group II, 0.05 mg; group
III, 0.1 mg; and, group IV, 0.2 mg (same patients as Chapter 3). The
presence or absence of itching was noted every three hours for a twenty-
four hour period. When requested by the patient, the standard procedure for
treatment was initiated.
The incidence of itching was: Group I: 14.3%; Group II: 21.6%; Group III:
48.6%; and, Group IV: 61.7%. Itch was treated by administering
promethazine intramuscularly in 2,9% (Group I); 8,1% (Group II); 10.8%
(Group III); and, 8.9% (Group IV) respectively. Only in group IV there was
1 patient who needed naloxon to treat itching. The incidence and severity of
itching is a dose related side effect in the dose range of 0.025 – 0.2 mg of
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intrathecal morphine. Itching even occurs after the low doses of intrathecal
morphine, but symptoms vanish after promethazine 25 mg intramuscularly.
Chapter 7
A non-invasive ultrasound imaging technique (BladderScan®) was used
prospectively in an attempt to reduce the need for catheterization of the
urinary bladder and the incidence of urinary tract infections after orthopedic
surgery. Over a 4-month period, in which 1920 patients were included,
catheterization was performed if there was no spontaneous voidance of
urine by 8 h after surgery. A total of 31% of these patients were
catheterized, and 18 patients developed urinary tract infections. In a 4-
month period, there were 2196 patients, catherization was performed only if
the bladder volume was more than 800 mL 8 h after surgery. The incidence
of catheterization decreased to 16%, and 5 patients developed urinary tract
infections. In our patients, measuring bladder volume reduced the need for
an urinary catheter and thereby the risk of urinary infection.
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Samenvatting
Hoofdstuk 1
Alhoewel er al meer dan twintig jaar morfine wordt toegediend in de
intrathecale ruimte om een optimale postoperatieve pijnstilling te bereiken is
ons uitgangspunt nog steeds niet bereikt: “selectieve spinale analgesie”. De
optimale plaats van toediening van opiaten is zo dicht mogelijk bij de
receptorplaats (het ruggenmerg), omdat dit de plaats is waar het effect
gegenereerd wordt. Om de klinisch effectiviteit van intrathecale opiaten te
verbeteren worden 2 mogelijkheden voorgesteld: 1. verlagen van de
intrathecale dosis van morfine en daarmee de ongewenste supraspinale
effecten verminderen of 2. verder onderzoek naar de ontwikkeling van zeer
selectieve endorfine mimetische stoffen.   
Hoofdstuk 2
In hoofdstuk 2 zijn de doelstellingen van dit proefschrift geformuleerd.
Vanuit theoretisch oogpunt lijkt de intrathecale toedieningsweg de meest
optimale om een goede postoperatieve pijnstilling te bereiken. De hypothese
was dat een lage dosis intrathecaal morfine een goede pijnstilling kan geven
terwijl de incidentie van bijeffecten gering behoeft te zijn.
Hoofdstuk 3
Deze studie is opgezet om de optimale dosis intrathecaal morfine voor
heupchirurgie vast te stellen. Deze optimale intrathecale dosis is
gedefinieerd als die dosis waarbij er een effectieve pijnstilling na de operatie
wordt verkregen welke vergezeld gaat met minimale bijwerkingen gedurende
24 uur na de heup vervangende operatie. Patiënten (n=143) welke een
heupvervangende operatie ondergingen werden gerandomiseerd naar 4
dubbelblinde groepen met een vaste bupivacaïne dosis maar verschillende
doseringen intrathecaal morfine: Groep I,  0,025 mg; Groep II, 0,05 mg;
Groep III, 0,1 mg; en Groep IV, 0,2 mg. Pijnscores, intraveneuze morfine
behoefte, op een patiënt gecontroleerde manier, en de aan morfine
gerelateerde bijwerkingen (ademhalingsdepressie, postoperatieve
misselijkheid en braken, jeuk en urineretentie) werden geregistreerd
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gedurende 24 uur na de operatie. Uitstekende postoperatieve pijnstilling was
aanwezig in alle groepen. De hoogste pijnscores werden gevonden in Groep
I. De gemiddelde hoeveelheid intraveneus toegediende morfine was: 23,7
mg, 17,8 mg, 10,9 mg and 9,9 mg, in respectievelijk Groep I, II, III, en IV
(p<0.01, Groep III en IV versus Groep I). Wij concludeerden dat 0,1 mg
intrathecaal toegediende morfine de optimale dosis is voor pijnstilling na
een heupvervangende operatie hetgeen gepaard gaat met de minste
bijwerkingen.
Hoofdstuk 4
De vraagstelling van deze studie was of de Ernst van de preoperatieve pijn
gerelateerd is aan de postoperatieve pijn en morfine consumptie. Zestig
patiënten welke een heupvervangende operatie ondergingen werden
bestudeerd. De preoperatieve pijnscore (Visual Analogue Scale = VAS) en
het analgetica gebruik werden 1 dag voor de operatie in kaart gebracht. Er
werden 3 groepen vastgesteld: die met geringe pijn (n=12, VAS score tussen
0 en 4), gematigde pijn (n=18, VAS score van 4 en 7) en ernstige pijn
(n=28, VAS score tussen 7 en 10). De postoperatieve pijnscores werden
geregistreerd in de eerste 24 uur na de operatie, evenals de hoeveelheid
morfine via de PCA pomp (PCA = patiënt gecontroleerde analgesie). Er
waren geen verschillen in de pijnscores op welk moment dan ook. Ernstige
preoperatieve pijn correleerde met een significant hoger morfine gebruik
postoperatief. De gemiddelde morfine opname gedurende de eerste 24 uur
postoperatief was: 19,2 mg in de groep met geringe preoperatieve pijn; 21,2
mg in de groep met gematigde preoperatieve pijn, en 29.5 mg in de groep
met ernstige preoperatieve pijn (p < 0.05 vergeleken met de beide andere
groepen). We concludeerden dat patiënten met een ernstige preoperatieve
pijn: a) zichzelf medicatie toedienen tot er gelijke postoperatieve pijn scores
ontstaan als patiënten met een geringe of gematigde preoperatieve pijn; en,
b) een grotere postoperatieve morfine behoefte hebben voor adequate
pijnstilling dan  patiënten met geringe of gematigde preoperatieve pijn.
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Hoofdstuk 5
Deze studie richtte zich op de vraag in hoeverre spinale opiaten bijdragen aan
postoperatieve misselijkheid en braken en vervolgens hoe effectief
metoclopramide de incidentie van postoperatieve misselijkheid en braken na
intrathecale toediening van morfine kan verminderen. Patiënten werden
toegewezen aan drie groepen die allen een heup- of knievervangende
operatie ondergingen. Groep I (n=200) kreeg een intrathecale anesthesie
door toediening van 20 mg bupivacaïne en 0,2 mg morfine, in groep II
(n=100) werd dezelfde intrathecale anesthesie toegediend met de toevoeging
van metocloramide 20 mg intramusculair na toediening van de anesthesie en
een tweede dosis van 20 mg metoclopramide intramusculair bij aankomst
op de verkoeverkamer. Tenslotte, groep III (n=100) kreeg een intrathecale
anesthesie toegediend met alleen 20 mg bupivacaïne.
De maximum PONV percentages waren 41,1%, 32,7% en 37% in
respectievelijk groep I, II en III. Het gebruik van anti-emetica was gelijk in
alle groepen. Het aantal patiënten dat een of meer extra antibiotica nodig
had in de eerste 24 uur na de operatie was 112 (56%), 57 (58%) en 60 (60%)
in respectievelijk groep I, II and III.
Toediening van metoclopramide gaf geen vermindering van de incidentie
van postoperatieve misselijkheid en braken. Deze studie liet geen relatie zien
tussen het gebruik van 0,2 mg intrathecaal toegediend morfine en de
incidentie van postoperatieve misselijkheid en braken gedurende de eerste
24 uur na de operatie.
Hoofdstuk 6
Het in dit hoofdstuk beschreven onderzoek werd verricht om vast te stellen of
ook lage doseringen intrathecaal morfine nog steeds jeuk veroorzaakt. Tevens
werd de standaard behandeling van jeuk met promethazine, en  voor
onhoudbare jeuk, naloxon beoordeeld.
Patiënten (n=143) welke een heupvervangende operatie ondergingen
(dezelfde patiënten als die in hoofdstuk 3) werden gerandomiseerd naar 4
dubbelblinde groepen met een vaste bupivacaïne dosis maar verschillende
doseringen intrathecaal morfine: Groep I,  0,025 mg, Groep II, 0,05 mg,
Groep III, 0,1 mg en Groep IV, 0,2 mg. De aan- of afwezigheid van jeuk
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werd iedere 3 uur geregistreerd gedurende de eerste 24 uur postoperatief.
Indien nodig werd een standaard behandeling voor jeuk ingesteld.
De incidentie van jeuk was: groep I: 14,3%; groep II: 21,6%; Groep III:
48,6%; en, Groep IV: 61,7%. Jeuk werd behandeld met toediening van 25
mg promethazine intramusculair in respectievelijk 2,9% (groep I); 8,1%
(groep II); 10,8% (groep III), en 8.9% (groep IV). Alleen in groep IV was er
1 patiënt welke naloxon nodig had om jeuk te behandelen. De incidentie en
Ernst van jeuk is dosis gerelateerd aan intrathecaal morfine in de range van
0,025 – 0,2 mg. Jeuk komt nog steeds voor bij lage doseringen morfine,
maar de symptomen verdwijnen na 25 mg promethazine intramusculair.
Hoofdstuk 7
Een niet invasieve ultrageluid techniek (Bladderscan®) werd op een
prospectieve wijze gebruikt om het blaasvolume te meten om daarmee het
aantal onnodige blaascatheterisaties en blaasinfecties na orthopedische
operaties te verminderen. In een periode van 4 maanden werden 1920
patiënten geincludeerd, waarbij blaascatheterisatie werd toegepast indien er
geen spontane diurese was 8 uur na operatie. Totaal werd er 31% van deze
patiënten de blaas gecatheteriseerd, en 18 patiënten ontwikkelde een
urineweginfectie. In de volgende periode van 4 maanden werden 2196
patiënten geincludeerd. Hierbij werd blaascatheterisatie alleen toegepast
indien het blaasvolume meer was dan 800 ml eveneens 8 uur na operatie.
Het aantal benodigde blaascatheterisaties daalde naar 18%, terwijl 5
patiënten een urineweginfectie ontwikkelde. Bij onze patiënten populatie
was er door de niet invasieve blaasvolume meting een verminderde
noodzaak voor blaascatheterisatie waarschijnlijk ook minder
urineweginfecties.
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Addendum
The preparation of 0.1 mg morphine in 4 mL bupivacaine
0.5%.
This addendum has been published:
The preparation of 0.1 mg morphine in 4 mL bupivacaine 0.5%.
R. Slappendel, B. Benraad, E.W.G. Weber, M.L.T. Bugter, R. Dirksen.
Anesth Analg 2000; 90(4):1000.  (letter to the editor)
which was a reply to: One drop of morphine added to local anaesthetics by
means of a 23 –gauge injection needle can relieve postoperative pain under
spinal anesthesia. Hirokatsu Toyoyama, Koh Mizutani, Yoshiro Toyoda.
Anesth Analg 2000; 90(4):1000
98
Addendum
The preparation of 0.1 mg morphine in 4 mL
bupivacaine.
A reply to: One drop of morphine added to local anesthetics by means of a
23 –gauge injection needle can relieve postoperative pain under spinal
anesthesia. Hirokatsu Toyoyama, Koh Mizutani, Yoshiro Toyoda.
We thank our Dr Toyoyama et al. for their response dealing with the
preparation of drugs in our article. However we do not support their
proposal that the anesthesiologists dilutes or adds the morphine themselves
to the bupivacaine. To guarantee the best quality of all mixtures which are
not purchased from the pharmaceutical industry we have these prepared by
our hospital pharmacy department. For all routes of administration of drugs
in our anesthesiology practice we must be certain that the exact
concentration of the drug is present and that a sterile method of preparation
has been used.
The actual method for preparation of the drug mixtures in our study (1),
bupivacaine 0.5% solution plus morphine 0.1 mg per 4 mL is given below.
A dry 2 L bottle is filled with 770 mL sterile water for injection. Five grams
bupivacaine hydrochloride 1.00 H2O PhEur (Pharmacopae European) and
7.70 grams Sodium chloride  H2O PhEur are weighed and added to the
water and mixed by a magnetic spatula. With a 10 mL pipette 25 mL
morphine (10mL=10mg) is added to the solution. Diluted hydrochloric acid
is added to a pH of 4.0. Sterile water is added up to 1 kg. When the sterile
water has been added the fluid is mixed during another 10 minutes by the
magnetic spatula until a homogeneous fluid exists. Next, nitrogen is led
through the solution for fifteen minutes. The bottle is closed with a paraffin
film.
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In an ampulla’s filling machine the ampulla’s are filled up to 5.3 mL.
Nitrogen needles are placed in the gas holders just before and after the filing
holders. The ampulla’s are sterilized in a steam autoclave for 16 min and 121
centigrade. The ampulla’s are labeled and numbered. A list of the labels is
kept in the pharmacy. For each batch of 70 ampulla’s, 60 ampulla’s are used
in clinical practice. The remaining ten ampulla’s are used for quality check.
The concentrations of morphine and bupivacaine are measured using high
pressure liquid chromatography (HPLC). The pH is measured by a glass
electrode. The osmolality is measured (norm 271 - 301). Finally the germ
number is determined before filtration and must be below 10 germs per mL.
In all, we strongly recommend to refrain from less methods. The safety
range of intrathecal morphine is just one drop.
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